From: The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
Characteristic, n (%) | CF (N = 61) | CDMF (N = 129) |
---|---|---|
MS medication before taking this therapy | ||
Copaxone (glatiramer acetate) | 17 (27.9 %) | 25 (19.4 %) |
Tysabri (natalizumab) | 9 (14.8 %) | 21 (16.3 %) |
No other med, this was first drug | 9 (14.8 %) | 14 (10.9 %) |
Tecfidera or Gilenya (Dimethyl Fumerate) | 6 (9.8 %) | 14 (10.9 %) |
Avonex (interferon beta1a) | 6 (9.8 %) | 11 (8.5 %) |
Rebif (interferon beta 1a) | 5 (8.2 %) | 24 (18.6 %) |
Betaseron (interferon beta1b) | 5 (8.2 %) | 4 (3.1 %) |
Other medicine not listed | 2 (3.3 %) | 1 (0.8 %) |
No other med, took break from treatment | 1 (1.6 %) | 12 (9.3 %) |
Aubagio (teriflunomide) | 1 (1.6 %) | 2 (1.6 %) |
Extavia (interferon beta 1b) | 0 (0.0 %) | 1 (0.8 %) |
Reasons switched to current therapy | ||
Previous medication side effects | ||
Yes | 33 (67.3 %) | 45 (44.1 %) |
No | 16 (32.7 %) | 57 (55.9 %) |
Wanted to take oral treatment | ||
Yes | 31 (63.3 %) | 63 (61.8 %) |
No | 18 (36.7 %) | 39 (38.2 %) |
Previous medication lack of effectiveness | ||
Yes | 19 (38.8 %) | 32 (31.4 %) |
No | 30 (61.2 %) | 70 (68.6 %) |
Struggled to take previous medication as prescribed | ||
Yes | 16 (32.7 %) | 16 (15.7 %) |
No | 33 (67.3 %) | 86 (84.3 %) |
Concerns regarding safety of previous medication | ||
Yes | 14 (28.6 %) | 28 (27.5 %) |
No | 35 (71.4 %) | 74 (72.5 %) |
Another reason not listed | ||
Yes | 9 (18.4 %) | 25 (24.5 %) |
No | 40 (81.6 %) | 77 (75.5 %) |
Change in health status | ||
Yes | 8 (16.3 %) | 24 (23.5 %) |
No | 41 (83.7 %) | 78 (76.5 %) |
Financial reasons | ||
Yes | 2 (4.1 %) | 4 (3.9 %) |
No | 47 (95.9 %) | 98 (96.1 %) |